Omeros
Omeros is a commercial-stage biopharmaceutical company developing first-in-class therapeutics for complement-mediated diseases, CNS disorders, and oncology. It commercializes YARTEMLEA, the only FDA-approved TA-TMA therapy, and has a pipeline including OMS1029, OMS527, and OncotoX-AML.
- Company typePublic
- Founded1994
- HeadquartersSeattle, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Omeros does
Omeros Corporation is a commercial-stage biopharmaceutical company headquartered in Seattle, Washington, founded in 1994 by Dr. Gregory Demopulos. The company develops first-in-class small-molecule and protein therapeutics targeting complement-mediated diseases, central nervous system disorders, and oncology. Its core proprietary platforms include a high-throughput GPCR deorphanization system that has unlocked 54 orphan G protein-coupled receptors, an antibody development platform leveraging a chicken B-cell lymphoma cell line, and the T-CAT anti-infective platform. The FDA-approved flagship product YARTEMLEA (narsoplimab-wuug) is a fully human monoclonal antibody targeting MASP-2, indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication of allogeneic HSCT occurring in up to 39-56% of recipients for which no approved therapy previously existed.
The company operates a direct specialty pharmaceutical sales model targeting US hospital and transplant center accounts, with Medicare and commercial payer reimbursement established through a permanent CMS J-code (J1289) effective July 2026 at $36,000 per single-dose vial and a typical treatment course of 8-10 vials. Revenue streams include YARTEMLEA product sales (Q1 2026: $9.89M from 30 accounts, with cash-flow positivity achieved in the first launch quarter), licensing and milestone payments from the October 2025 Novo Nordisk transaction for zaltenibart (OMS906, a MASP-3 inhibitor for PNH) worth up to $2.1 billion including a $340M upfront, and government research grants including a $6.69M NIDA grant supporting OMS527 development for cocaine use disorder. The pipeline includes OMS1029 (long-acting MASP-2 inhibitor in Phase 1), OMS527 (PDE7 inhibitor for addiction), OncotoX-AML (preclinical oncology), and CAR-T/adoptive T-cell therapy discovery programs. Omeros is publicly traded on NASDAQ (OMER) with a March 2026 market capitalization of approximately $780M and FY2025 cash position of $135.3M against $226.6M of debt.
Omeros firmographics
Firmographics- Name
- Omeros
- Legal name
- Omeros Corporation
- Website
- https://omeros.com
- Company type
- Public
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Omeros is a commercial-stage biopharmaceutical company developing first-in-class therapeutics for complement-mediated diseases, CNS disorders, and oncology. It commercializes YARTEMLEA, the only FDA-approved TA-TMA therapy, and has a pipeline including OMS1029, OMS527, and OncotoX-AML.
- Ownership category
- akta.pro rank
Omeros industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
- akta.pro secondary industries
- Rare Renal & Nephrology Disorder Therapies (HLAIAIAI), CAR-T & TCR-T Therapies (HLAAABAC)
Keywords
Where Omeros is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Omeros business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- YARTEMLEA Product Sales: Revenue from commercial sales of FDA-approved YARTEMLEA (narsoplimab-wuug) for TA-TMA treatment. Priced at $36,000 per single-dose vial with typical treatment course of 8-10 vials. Launched January 2026 in US market.
- Zaltenibart Licensing and Milestone Payments: Novo Nordisk partnership includes upfront payment of $340 million plus potential milestone payments up to $2.1 billion total for global rights to zaltenibart. Royalty payments on future sales.
- Government Research Grants: $6.69 million grant from National Institute on Drug Abuse (NIDA) for development of OMS527 in cocaine use disorder, supporting preclinical and clinical trials.
- Narsoplimab for Lupus Nephritis: Phase 2 clinical trials ongoing with potential for future commercial revenues in lupus nephritis indication. Reduced proteinuria by 70% in Phase 2 trials.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | YARTEMLEA commercial vial pricing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Omeros product offering
Product offeringCore offering
Omeros is a commercial-stage biopharmaceutical company that develops and markets therapeutics targeting the complement system, central nervous system disorders, and oncology. Its commercial product YARTEMLEA (narsoplimab-wuug) is the first and only FDA-approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The pipeline also includes zaltenibart licensed to Novo Nordisk, the OMS527 PDE7 inhibitor for addiction, OMS1029 long-acting MASP-2 inhibitor, and oncology programs including OncotoX-AML and CAR-T/adoptive T-cell therapies.
Product overview
Omeros is a biopharmaceutical company with a deep and diverse pipeline of first-in-class small-molecule and protein therapeutics. The company's portfolio centers on complement-mediated diseases, central nervous system disorders (particularly addiction), and oncology. Key products include YARTEMLEA (narsoplimab-wuug), an FDA-approved MASP-2 inhibitor for TA-TMA; zaltenibart (OMS906), a MASP-3 inhibitor licensed to Novo Nordisk; OMS527, a PDE7 inhibitor for addiction disorders; and OMS1029, a long-acting MASP-2 inhibitor. The company also has discovery platforms including a GPCR deorphanization technology, an antibody development platform, the T-CAT anti-infective platform, and oncology programs including OncotoX-AML and CAR T/adoptive T cell therapies. Omeros has retained exclusive worldwide commercial rights for all products except zaltenibart.
Differentiator
Problem solved
Functional benefit
Brands
- YARTEMLEA (narsoplimab-wuug): FDA-approved fully human monoclonal antibody targeting MASP-2 for treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
- Zaltenibart (OMS906)
- OMS527
- OMS1029
- OncotoX-AML
- T-CAT
Products and services
- YARTEMLEA (narsoplimab-wuug) FDA-approved fully human monoclonal antibody targeting MASP-2, indicated for treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in patients aged 2 and older. Sold to hospitals, transplant centers, and specialty pharmacies at $36,000 per single-dose vial.
- Zaltenibart (OMS906) Humanized monoclonal antibody targeting MASP-3, the key activator of the alternative pathway of complement. Licensed to Novo Nordisk for development in paroxysmal nocturnal hemoglobinuria (PNH) and other rare hematologic and renal disorders.
- OMS527 (PDE7 Inhibitor) Small-molecule phosphodiesterase 7 inhibitor that modulates dopamine levels in brain areas responsible for addiction. Being developed for cocaine use disorder, nicotine, opioid, and alcohol addiction.
- OMS1029 Long-acting second-generation antibody targeting MASP-2 with expected once-monthly to once-quarterly subcutaneous or intravenous dosing for complement-mediated diseases.
- OMS405 Pipeline candidate included in the Omeros pipeline overview of complement and inflammation programs.
- OncotoX-AML Cancer therapeutic platform targeting acute myeloid leukemia (AML) through a novel oncotoxin approach; preclinical candidate with up to 99% reduction in myeloid progenitor cells demonstrated in nonhuman primate studies.
- CAR T and Adoptive T Cell Therapies Program Proprietary cellular therapy approach combining GPR174, adenosine A2, and other target inhibitors to enhance T cell function for cancer immunotherapy, designed to work without requiring cellular engineering.
Quantifiable outcome
- 61-68% complete response rate in TA-TMA patients vs. ~20% historical control
- +5 more outcomes
Companies that use Omeros
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles2 records
Omeros technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Omeros partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship, core and minor.
- Novo NordiskflagshipNovo Nordisk acquired global rights to zaltenibart (OMS906), Omeros' clinical-stage MASP-3 inhibitor for rare blood and kidney disorders including PNH. Deal includes $340 million upfront payment and up to $2.1 billion in milestone and royalty payments. Novo Nordisk is developing zaltenibart in Phase 3 trials for PNH and investigating in other rare hematologic and renal disorders. Transaction closed December 1, 2025.
- University of CambridgecoreResearch collaboration establishing the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR) to characterize the role of complement system in endothelial injury implicated in thrombotic microangiopathies and glomerulonephropathies.
- Memorial Sloan Kettering Cancer CentercoreMedical professionals from Memorial Sloan Kettering co-chairing EBMT 2026 industry session on TA-TMA treatment advances with YARTEMLEA, providing clinical expertise and research collaboration.
- Children's Healthcare of AtlantacoreMedical professionals from Children's Healthcare of Atlanta co-chairing EBMT 2026 industry session on TA-TMA treatment advances, contributing pediatric clinical expertise.
- Rayner SurgicalminorOmeros sold OMIDRIA to Rayner Surgical in 2021 in a transaction valued in excess of $1 billion, divesting the ophthalmic surgical product to focus on complement and CNS pipeline.
- National Institute on Drug Abuse (NIDA)core$6.69 million, 3-year grant to support preclinical cocaine interaction studies and clinical trial evaluating OMS527 safety and efficacy in patients with cocaine use disorder. Part of NIH efforts to address unmet needs in addiction treatment.
Scale indicators21 records
Recent moves10 records
Expansion highlights7 records
Omeros competitors and assessment
Company assessmentDirect peers
- Alexion (AstraZeneca Rare Disease): Market leader in complement-mediated therapeutics (Soliris/Ultomiris are C5 inhibitors approved for PNH, aHUS). Directly comparable to Omeros in complement pathway targeting and rare disease commercial focus.
- Apellis Pharmaceuticals: Develops complement therapeutics (Empaveli/Aspaveli, a C3 inhibitor for PNH). Direct competitor in complement biology and rare hematologic/renal diseases.
- argenx: Commercial-stage rare disease antibody biopharmaceutical company (Vyvgart for myasthenia gravis). Comparable in antibody platform, rare disease focus, and commercial-stage growth profile.
- Travere Therapeutics: Rare disease biopharma with focus on kidney disorders (Filspari for IgA nephropathy). Directly overlaps with Omeros's narsoplimab IgA nephropathy indication and rare renal disease focus.
- ChemoCentryx: Acquired by Amgen in 2022, developed complement pathway inhibitor (Tavneos) for ANCA-associated vasculitis. Comparable complement biology platform and rare autoimmune disease focus.
Broad incumbents
- BioMarin Pharmaceutical: Established rare disease biopharmaceutical company with multiple commercial products addressing genetic and orphan conditions. Comparable in rare disease commercialization and orphan drug development strategy.
- Vertex Pharmaceuticals: Commercial-stage rare disease biopharma with strong specialty drug commercialization capabilities and pipeline expansion via business development. Comparable in rare disease commercial execution.
- Jazz Pharmaceuticals: Specialty biopharma with rare disease CNS focus (Xywav, Epidiolex) and track record of transformative acquisitions (similar to Omeros's deal-making approach with Novo Nordisk and Rayner Surgical).
Emerging players
- Alnylam Pharmaceuticals: RNAi therapeutics company with multiple rare disease products (Onpattro, Givlaari, Amvuttra). Comparable in rare disease focus, novel modality therapeutics, and pipeline-driven valuation model.
- Akari Therapeutics: Emerging complement therapeutics company targeting PNH and other complement-mediated diseases. Comparable in complement pathway focus and rare hematologic disease development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Omeros social profiles
Digital presenceOmeros compliance and trust
Trust signalCompliance5 records
Omeros financial estimates
Financial estimateRevenue estimate
Valuation estimate
Omeros leadership team
Management profileNumber of profiles
Profiles9 records
Omeros subsidiaries and ownership
Company hierarchySubsidiaries2 records
Omeros funding detail
Funding detailFunding overview
Funding rounds26 records
Investors20 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Omeros M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Omeros
What does Omeros do?
Omeros is a commercial-stage biopharmaceutical company that develops and markets therapeutics targeting the complement system, central nervous system disorders, and oncology. Its commercial product YARTEMLEA (narsoplimab-wuug) is the first and only FDA-approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The pipeline also includes zaltenibart licensed to Novo Nordisk, the OMS527 PDE7 inhibitor for addiction, OMS1029 long-acting MASP-2 inhibitor, and oncology programs including OncotoX-AML and CAR-T/adoptive T-cell therapies.
Is Omeros a public or private company?
Omeros is a public company. It is classified as public and is currently operating.
When was Omeros founded?
Omeros was founded in 1994. It employs 101 to 250 people.
Where is Omeros based?
Omeros is headquartered in Seattle, United States, in the North America region.
How does Omeros make money?
Four revenue lines are on record. YARTEMLEA Product Sales are the primary driver. The others are zaltenibart Licensing and Milestone Payments, government Research Grants and narsoplimab for Lupus Nephritis.
Who are Omeros's main competitors?
Direct peers on record are Alexion (AstraZeneca Rare Disease), Apellis Pharmaceuticals, argenx, Travere Therapeutics and ChemoCentryx. Broad incumbents are BioMarin Pharmaceutical, Vertex Pharmaceuticals and Jazz Pharmaceuticals. Emerging players are Alnylam Pharmaceuticals and Akari Therapeutics.
Does Omeros have an API?
No public API is recorded for Omeros.
What industry is Omeros in?
Omeros's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAIAIAI, Rare Renal & Nephrology Disorder Therapies. Its NAICS code is 325414 and its SIC code is 2836.